Cross-sectional biomarker data from the Colombian kindred confirm models of biomarker progression, but suggest an earlier drop in brain metabolism.
Partnership will sequence the entire genomes of 3,000 patients.
Three new therapies enhance the therapeutic effects of levodopa.
A study reports a high incidence of criminal behavior in people with frontotemporal dementia. Especially for the undiagnosed, real trouble lies ahead.
Sil1’s presence keeps the endoplasmic reticulum from activating a chronic stress response.
Like a second skin, a new kind of neural implant is as compliant as the protective dura membrane that envelops the central nervous system.
Measuring total prion protein in cerebrospinal fluid could help clinicians differentiate between prion disease and rapidly progressing forms of dementia.
Alzforum looks back on last year's research newsmakers.
Posing as the amino acid tyrosine, the anti-aging compound resveratrol turns on a new target, PARP1.
Researchers mimic neuroprotective RNAs with stable DNAs that can do the same job.
Scientists claim that MRI detects an Aβ oligomer-specific probe delivered to the mouse brain through the nose.
Tiny spheres full of oxygen soothe neuroinflammation and fight neurodegeneration, researchers reported at SfN. The concept may seem strange, but AD trials are on the horizon.
CTAD Shows Alzheimer’s Field Trying to Reinvent Itself Rusty Unleashed: Forget Disease Modification, Go For Big Effect From Shared CAP, Secondary Prevention Trials are Off and Running Immunotherapy I: Baby Steps, but No Breakthroughs Immunotherapy II: ...
In mouse models of AD, one astrocyte purinergic receptor makes glia hyperactive, while another may suppress memory. Both are upregulated in the AD brain, researchers report.
Researchers at CTAD added to growing evidence that brain amyloid accumulation presages cognitive decline, although several different factors influence how fast that decline will happen in a given person.